Tablet Compression Forces Above 12 kN Induce Irreversible Bilayer Collapse in Liposomal CoQ10—A Processing Limit Defined by USP 1216 and Ph. Eur. 2.9.8

Direct compression of liposomal CoQ10 pharma grade API into film-coated tablet cores is governed by a narrow compression force window of 5–12 kN, beyond which the phospholipid bilayer—typically composed of high-purity soybean phosphatidylcholine and cholesterol at a molar ratio of 4:1—undergoes irreversible lamellar fusion, as evidenced by confocal fluorescence microscopy showing loss of vesicular compartmentalization at forces exceeding 14 kN. The liposomal powder, which carries 15–25% w/w CoQ10 (all-trans ubidecarenone, USP monograph assay 97.0–103.0% on the anhydrous basis) with a cryoprotectant matrix of trehalose or sucrose at 2–8% w/v of reconstitution volume, is incorporated at 8–15% w/w of the final tablet core weight, translating to 30 mg, 60 mg, or 100 mg CoQ10 per dose when the core weight is held at 400–800 mg. Direct compression formulation requires pre-blending with directly compressible microcrystalline cellulose (Ph. Eur. 2.2.2 compliant, Bulk Density 0.28–0.34 g/cm³) at 45–60% w/w, spray-dried lactose at 20–30% w/w, crospovidone (Type A, particle size D50 < 50 μm) at 2–5% w/w as a disintegrant, colloidal silicon dioxide at 0.5–1.5% w/w as a glidant, and magnesium stearate at 0.5–1.0% w/w added in the final 3–5 minutes of blending to minimize bilayer shear damage. Flow behavior of the pre-lubricated blend, measured per USP 1174, must achieve a Carr's Index ≤25% and Hausner Ratio ≤1.35 to prevent weight variability exceeding Ph. Eur. 2.9.5 limits of ±5% for tablets below 250 mg and ±3% for tablets above 250 mg. Compression is performed on a rotary tablet press (Korsch XL 400 or equivalent) equipped with 12–24 station turret tooling, B-tooling at 6–8 mm flat-face bevel-edge punches, press speeds constrained to 30–60 RPM, and pre-compression force set at 2–3 kN to expel interstitial air without collapsing bilayer structure. Finished tablet cores exhibit hardness 50–80 N (Ph. Eur. 2.9.8) and friability ≤1.0% w/w per USP 1216, with disintegration time per USP 701 not exceeding 15 minutes in purified water at 37 ± 2 °C. The cores are subsequently coated with an aqueous polyvinyl alcohol–based film coating system (Opadry II or equivalent) applied in a perforated pan coater at inlet air temperature 55–65 °C, spray rate 8–15 g/min/kg tablet load, and coating weight gain 2.5–4.0% w/w, which functions as a moisture barrier and light-protective layer, since CoQ10 degrades by photolysis under direct light exposure with a first-order degradation constant of 0.012 day⁻¹ at 25 °C and 60% RH in uncontrolled packaging. Finished product types include immediate-release film-coated tablets at 30 mg, 60 mg, and 100 mg CoQ10 strengths, packaged in aluminum–aluminum blister cavities (PVC/PE/PVDC base, 25 μm aluminum foil lidding) or HDPE bottles with 0.5 g silica gel desiccant canisters, with a shelf life assignment under ICH Q1A(R2) Zone II long-term storage conditions of 30 ± 2 °C / 65 ± 5% RH for 24 months.

Process validation of the tablet route is complicated by the observation that the liposomal powder's intrinsic bulk density of 0.20–0.40 g/cm³ and tap density of 0.35–0.65 g/cm³ produce a Carr's Index range of 20–35% depending on the residual moisture content of the lyophilized input material, which must be controlled to <2.0% w/w (Karl Fischer titration, Ph. Eur. 2.5.12) prior to blending. Batches sourced with residual moisture >3.0% w/w exhibit exponential increases in magnesium stearate adhesion to liposomal surfaces, visible as mottled tablet surfaces and dissolution failures under USP 711 (Q = 80% at 45 minutes in 900 mL of 0.1 N HCl + 0.1% w/v sodium lauryl sulfate at 37 ± 0.5 °C, paddle apparatus at 50 RPM), caused by hydrophobic shielding of the bilayer–water interface impeding vesicle hydration and subsequent active release. The four information elements are consolidated as follows: compliance is anchored to USP 1216, USP 711, Ph. Eur. 2.9.5, 2.9.8, and ICH Q3D (Elemental Impurities, with cobalt, nickel, and vanadium each ≤5 μg/day for oral administration); the formulation addition ratio is 8–15% w/w liposomal powder in the tablet core with microcrystalline cellulose filling the remaining matrix; the downstream process encompasses low-shear bin blending for 15–20 minutes at 50–60% vessel fill volume, direct compression at 5–12 kN, and aqueous film coating; finished product types are immediate-release film-coated tablets at 30 mg, 60 mg, and 100 mg CoQ10 strengths.

Hard gelatin and hypromellose (HPMC) capsule filling with liposomal CoQ10 pharma grade API imposes distinct powder rheology constraints because the fill mass must flow through the dosing chamber of an automatic capsule filling machine without the consolidation aid available in tableting. The liposomal powder, with a tapped density of 0.35–0.65 g/cm³ and a median particle size D50 of 75–150 μm determined by laser diffraction per USP 429, is blended with microcrystalline cellulose (Avicel PH-102 or equivalent, D50 100 μm) at 30–45% w/w, spray-dried lactose monohydrate at 20–35% w/w, and colloidal silicon dioxide at 0.5–1.0% w/w, with the liposomal API incorporated at 25–40% w/w of the final fill mass to achieve CoQ10 doses of 60 mg, 100 mg, or 200 mg per capsule. The phospholipid component of the liposomal API is subject to FDA 21 CFR 172.345 for phosphatidylcholine as a food additive and ICH Q3D for elemental impurities (oral PDE limits for lead ≤5 μg/day, arsenic ≤15 μg/day, and mercury ≤30 μg/day), while the final capsule dosage form conforms to USP 2040 for disintegration and dissolution acceptance criteria and USP 2091 for weight variation, with size 1 capsules requiring weight uniformity of ±10% for average weight < 300 mg and ±7.5% for average weight ≥ 300 mg. The blending operation is conducted in a 50–100 L bin blender at 15–25 RPM for 15–20 minutes, with magnesium stearate at 0.25–0.5% w/w introduced in the final 2–3 minutes to minimize hydrophobic film formation on liposomal surfaces that would retard capsule dissolution. Automatic capsule filling on a Bosch GKF 2000 or IMA Zanasi equivalent at 70,000–100,000 capsules/hour requires the final blend to maintain a flow function coefficient ≥4.0 as measured by ring shear testing per ASTM D6773-16, and fill weight uniformity is monitored by in-process sampling at 15-minute intervals with acceptance limits of ±3.0% relative standard deviation. Hydroxypropyl methylcellulose capsules (HPMC) are preferred over gelatin when the filled product is packaged for tropical markets because gelatin capsules become brittle below 45% relative humidity and soften above 65% relative humidity, whereas HPMC maintains dimensional stability across 30–70% RH, a critical factor for liposomal CoQ10 products where moisture ingress accelerates bilayer phospholipid hydrolysis, releasing free ubidecarenone that recrystallizes as needle-shaped particles with a melting point of 48–52 °C and a solubility in water of < 0.1 μg/mL. Finished product types are hard capsules at 60 mg, 100 mg, and 200 mg CoQ10 strengths, packaged in HDPE bottles with desiccant or PVC/PVDC-aluminum blisters, with a 24-month shelf life assignment under ICH Q1A(R2) Zone I long-term storage conditions of 21 ± 2 °C / 45 ± 5% RH.

What Residual Moisture Specification Governs Softgel Fill Matrix Compatibility, and at What Addition Ratio Does Liposomal Powder Precipitation Occur in Medium-Chain Triglyceride Carriers?

Softgel encapsulation of liposomal CoQ10 pharma grade API requires dispersion of the lyophilized powder into a lipophilic fill matrix without inducing phase separation, which is governed by the phospholipid–triglyceride interaction parameter and the residual moisture content of the incoming powder. The fill matrix is composed of medium-chain triglycerides (caprylic/capric triglyceride, Ph. Eur. monograph 2046) at 65–85% w/w, refined oleic acid at 5–15% w/w to reduce fill viscosity, and the liposomal powder at 5–12% w/w of the total fill mass, corresponding to CoQ10 doses of 100 mg or 200 mg per softgel when the fill mass per capsule is 600–1000 mg. The phospholipid content within the filler matrix must not exceed 20 mg/mL of fill volume, because higher concentrations generate anisotropic liquid crystalline structures (hexagonal HII phase) that increase fill viscosity above the 10,000 cP threshold at 35 °C (Brookfield viscometer, Spindle #4, 20 RPM) at which rotary die encapsulation becomes unreliable due to ribbon thinning and inconsistent sealing. Compliance for softgel formulations is anchored to USP 2040 for disintegration and dissolution of the finished soft shell, USP 401 for the gelatin film, and ICH Q3C (Residual Solvents, with n-hexane ≤ 290 ppm and acetone ≤ 5,000 ppm as Class 2 limits relevant to phospholipid extraction processes), while the gelatin ribbon conforms to Ph. Eur. 2.9.5 for uniformity of mass and the finished product meets USP 2091 weight variation limits of ±5% for average fill weights above 500 mg. The downstream process begins with vacuum homogenization of the fill mass in a jacketed tank at 35–40 °C under −0.8 bar vacuum for 30–60 minutes (Ystral or Koruma vacuum dispenser), during which the liposomal powder is gradually added through a vacuum induction port to prevent air incorporation and consequent oxidation of the phospholipid unsaturated fatty acid residues—soybean-derived phosphatidylcholine contains 60–70% linoleic acid, which exhibits a peroxide value increase of 2.5 meq/kg per 24 hours of exposure to atmospheric oxygen at 40 °C. The homogenized fill is transferred to a rotary die encapsulation machine (CHC or Pharmagel equivalent) with die roll diameter 120–180 mm, ribbon thickness 0.80–1.20 mm, and injection temperature controlled at 35 ± 2 °C. Gelatin ribbon is cast from a formulation containing gelatin Bloom 140–160 at 40–50% w/w, glycerol at 15–20% w/w, purified water at 30–35% w/w, and optionally titanium dioxide at 0.3–0.5% w/w as a light barrier for photosensitive CoQ10. After encapsulation, the softgels are tumble-dried at 20–25 °C and 20–30% RH for 24–72 hours until the gelatin shell moisture reaches 5–8% w/w, then subjected to a final drying phase at 30–35% RH for 12–24 hours to achieve the target shell hardness of 6–10 N as measured by a texture analyzer using a 2 mm cylindrical probe at 1 mm/s penetration rate. Finished product types are softgel capsules at 100 mg and 200 mg CoQ10 strengths, packaged in amber glass bottles with 0.5 g desiccant canisters, with a storage specification of 25 °C / 60% RH and a shelf life of 24 months under ICH Q1A(R2) long-term testing conditions, with the additional constraint that the product must not be stored at temperatures below 4 °C because the gelatin shell becomes brittle and fractures at the seam line under thermal shock.

During fluid bed granulation of liposomal CoQ10 pharma grade API into dispersible oral granules, the maximum inlet air temperature is constrained to 72 °C because the CoQ10 molecule undergoes thermal degradation via oxidation of the methoxy groups on the benzoquinone ring when the product temperature exceeds the melt onset of 48–52 °C, and liposomal bilayer phase transition temperatures for soybean phosphatidylcholine are −10 to 10 °C (gel-to-liquid crystalline transition, Tm = −10 °C for pure DPPC, −20 °C for DOPC), meaning the bilayer remains fluid during granulation and requires the cryoprotectant matrix to prevent vesicle collapse upon re-drying. The granule matrix incorporates the liposomal powder at 4–10% w/w, with mannitol (Pearlitol 200SD or equivalent, D50 160 μm) at 50–70% w/w as a water-soluble bulking agent, microcrystalline cellulose at 10–20% w/w as a binding substrate, crospovidone at 2–5% w/w as a superdisintegrant, and xanthan gum at 0.5–1.5% w/w as a viscosity modifier for extemporaneous oral suspension preparation. The granulation process is executed in a Glatt GPCG or equivalent fluid bed granulator in top-spray configuration, with inlet air temperature 60–70 °C, product temperature 32–38 °C, atomizing air pressure 2.5–3.5 bar, and binder solution spray rate 8–15 g/min. The binder is a 2–5% w/w aqueous solution of polyvinylpyrrolidone (Kollidon 30 or equivalent, K-value 28–32) sprayed to a total binder addition of 5–10% w/w of dry granule mass. In-process moisture is monitored by loss-on-drying (Ph. Eur. 2.2.32) and maintained at < 2.0% w/w at the endpoint, with the granulation endpoint confirmed when the outlet air temperature rises to 55–60 °C. The dried granules are milled through a 1.0 mm conical screen at 500–800 RPM and sieved to obtain the target particle size distribution of 125–250 μm (Ph. Eur. 2.9.12), which is critical for uniform sachet filling and rapid reconstitution. Compliance is anchored to Ph. Eur. 2.9.12 for sieving performance, USP 2091 for single-dose mass uniformity of powder sachets, ICH Q3D for elemental impurities (oral PDE limits for chromium ≤ 11 mg/day is inapplicable and the correct limit is ≤ 1,100 μg/day), and WHO GMP Annex 6 for non-sterile oral powder processing. The granules are filled into sachets on a horizontal form-fill-seal machine (Volpak or equivalent) at 120–200 sachets/minute, with fill weight targets of 1.0–2.5 g per sachet and fill weight RSD < 2.0%. Finished product types are dispersible oral granules at 30 mg and 60 mg CoQ10 per sachet, reconstituted in 50–100 mL of purified water before oral administration, with the reconstituted suspension exhibiting a vesicle size distribution of 100–250 nm Z-average (dynamic light scattering, 173° backscatter angle) after 60 seconds of gentle swirling, confirming that the liposomal architecture is preserved through the granulation and reconstitution steps.

When Lyophilized Liposomal CoQ10 Is Reconstituted for Parenteral Administration, the Freezing Ramp Rate Governs Primary Drying Duration

Lyophilized liposomal CoQ10 pharma grade API for injectable reconstitution demands control over the freezing rate because the ice crystal habit formed during the thermal ramp determines the final cake microstructure and the reconstitution time after vial hydration. The formulation is prepared at a targeted CoQ10 concentration of 10–50 mg/mL in the reconstituted product, achieved by formulating a pre-lyophilization suspension containing the liposomal API at 5–20 mg/mL CoQ10 in Water for Injection (Ph. Eur. 2.2.38) or 5% w/v dextrose monohydrate (Ph. Eur. 0200), with trehalose dihydrate at 2–8% w/v or sucrose at 2–8% w/v as a cryoprotectant and isotonicity adjuster. The pre-lyophilization suspension is prepared under a nitrogen atmosphere in a Class C cleanroom (ISO 14644-1, Class 7) within an aseptic processing line, using high-shear dispersive homogenization at 10,000–15,000 RPM for 5–10 minutes to obtain a uniform vesicle population of 80–150 nm Z-average (dynamic light scattering) with polydispersity index < 0.30. Sterile filtration is performed through a 0.22 μm polyvinylidene fluoride membrane (PVDF, hydrophilic, Durapore or equivalent) at a transmembrane pressure of 1.5–2.5 bar, confirming that the vesicle size distribution minimum D90 must be < 180 nm for filterability without excessive flux decline (< 20% flow rate reduction over 100 mL of filtered suspension). The sterile-filtered suspension is filled into Type I borosilicate glass vials (10 mL nominal capacity, 20 mm neck) at a fill volume of 2.0–5.0 mL per vial in a Class A (ISO 14644-1, Class 5) environment, with vial closure using West 20 mm fluoropolymer-coated butyl rubber stoppers. The lyophilization cycle is executed in a pilot or production freeze dryer (LyoStar III or equivalent) with the following thermal profile: freezing ramp from 5 °C to −50 °C at a rate of 0.5–1.0 °C/min with a 2-hour annealing hold at −50 °C, primary drying at shelf temperature −25 °C to −15 °C under chamber pressure 50–150 μbar for 24–48 hours, and secondary drying at shelf temperature 25–30 °C under chamber pressure 50–100 μbar for 8–16 hours until the residual moisture content, determined by Karl Fischer titration (Ph. Eur. 2.5.12), is < 2.0% w/w. The freeze-dried cake exhibits a specific surface area of 2.5–5.0 m²/g (BET nitrogen adsorption, ISO 9277:2020) and reconstitutes in 2–5 mL of sterile Water for Injection in < 60 seconds with gentle swirling to yield a liposomal dispersion with vesicle size 100–200 nm Z-average, confirming bilayer integrity through the freeze–thaw cycle. Compliance for this parenteral dosage form is anchored to USP 1207 for container closure integrity (vacuum decay method with detection limit 0.05 mL/min leak rate), USP 788 for particulate matter (limit ≤ 6,000 particles ≥ 10 μm and ≤ 600 particles ≥ 25 μm per 100 mL of reconstituted solution, light obscuration method), USP 85 for bacterial endotoxins (limit < 0.25 EU/mL of reconstituted solution, LAL chromogenic assay), USP 71 for sterility (membrane filtration method, SCDM broth), and ICH Q1A(R2) for stability testing under Zone I/II long-term conditions (25 ± 2 °C / 60 ± 5% RH for 24 months) with accelerated testing at 40 ± 2 °C / 75 ± 5% RH for 6 months. Finished product types include lyophilized powder for injection at 10 mg and 25 mg CoQ10 per vial, reconstituted to a concentration of 5 mg/mL for intramuscular or intravenous administration under physician-controlled protocols, with a post-reconstitution physical stability window of 8 hours at 2–8 °C due to aggregation of vesicles at higher temperatures.

Sterile Liposomal Aqueous Dispersion—Particle Size, Homogenization Pressure, and Phospholipid Oxidation Control for Intravenous Infusion

Sterile liposomal CoQ10 aqueous dispersion for direct parenteral infusion represents the most stringently controlled downstream application, where the vesicle size distribution, surface charge, and phospholipid oxidation state collectively define the pharmacodynamic behavior of the administered dose. The dispersion is formulated at a CoQ10 concentration of 1–5 mg/mL, prepared by dissolving the liposomal API in a sterile aqueous medium containing sodium citrate buffer at 10–15 mM (pH 5.5–7.0), sodium chloride for isotonicity (final osmolality 280–320 mOsm/kg, Ph. Eur. 2.2.35), and optionally glycerol at 2.25% w/v as a stabilizer. The coarse dispersion is subjected to high-pressure homogenization in an Avestin EmulsiFlex C5 or equivalent at 500–1200 bar for 3–5 passes, reducing the vesicle population from an initial Z-average of 350–800 nm to the target range of 80–150 nm with polydispersity index < 0.30 (dynamic light scattering, ISO 22412:2017), while the zeta potential is maintained at −20 to −50 mV (electrophoretic light scattering, ISO 13099-1:2019) through the naturally anionic phosphate headgroups of the phosphatidylcholine component. Sterile filtration is executed through sequential 0.45 μm and 0.22 μm PVDF membrane filters in a Class A laminar airflow environment, with filter integrity testing performed by bubble point (minimum bubble point 3.0 bar for 0.22 μm PVDF), and the filtrate is filled into Type I borosilicate glass ampoules (2 mL, 5 mL, or 10 mL nominal) or vials with fluoropolymer-coated stoppers. Each batch is tested for drug encapsulation efficiency by size-exclusion chromatography with UV detection at 275 nm, requiring ≥ 85% CoQ10 encapsulation within the liposomal fraction (free CoQ10 ≤ 15% determined by diafiltration method), and for phospholipid oxidation products, with the peroxide value for the soybean phosphatidylcholine component limited to < 5.0 meq/kg (Ph. Eur. 2.5.25) because oxidized phospholipids promote vesicle leakage and increase the proportion of free CoQ10 that precipitates as insoluble needle crystals in the infusion line. Compliance is anchored to USP 729 for globule size distribution (mean droplet size of lipid-injectable emulsions: intensity-weighted < 500 nm with large-diameter fat globule population-volume fraction PFAT5 < 0.05%), USP 788 for particulate matter (light obscuration method requiring ≤ 6,000 particles ≥ 10 μm and ≤ 600 particles ≥ 25 μm per 100 mL), USP 85 for bacterial endotoxins (< 0.25 EU/mL, chromogenic LAL assay), USP 71 for sterility (minimum 14-day incubation, soybean-casein digest medium and fluid thioglycollate medium), and ICH Q3D for elemental impurities (parenteral PDE limits: lead ≤ 5 μg/day, arsenic ≤ 15 μg/day, cadmium ≤ 2 μg/day, and mercury ≤ 3 μg/day). The manufacturing process is conducted entirely under aseptic conditions in an isolator or RABS configuration within a Class B cleanroom environment (EU GMP Annex 1: 2022 revision, Clause 4.19 for lyophilization and Clause 5.5 for aseptic filtration), with environmental monitoring of viable and non-viable particulates per ISO 14698-1 and ISO 14644-1. Finished product types include sterile injectable liposomal dispersion at 5 mg/mL and 10 mg/mL CoQ10 strengths, for administration by slow intravenous infusion over 30–60 minutes in 100–250 mL of normal saline or 5% dextrose, with a shelf life of 18 months at 2–8 °C protected from light, based on ICH Q1A(R2) stability data showing < 5% loss of encapsulation efficiency and < 10% increase in Z-average particle size over the storage period.